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BACKGROUND Cangrelor, an intravenous, rapidly acting P2Y12 in-
hibitor, is superior to clopidogrel in reducing ischemic events in PCI
patients with stable ischemic heart disease and acute coronary syn-
dromes. We examined the safety and efﬁcacy of cangrelor in relation
to the extent of coronary artery disease.
METHODS We studied a prespeciﬁed modiﬁed intention to treat
population of patients with single vessel and multivessel coronary
disease. The primary efﬁcacy outcome was the composite of death,
myocardial infarction (MI), ischemia-driven revascularization (IDR),
and stent thrombosis (ST) at 48 hours. Kaplan Meier analysis of the
primary outcome was performed through 30 days. The safety outcome
was non-CABG GUSTO severe bleeding at 48 hours.
RESULTS Among 10,921 patients, 5,296 (48%) had single vessel disease
(SVD) and 5,625 (52%) had multivessel disease (MVD). Patients with MVD
were older (65 vs. 63 years), less often female (25% vs. 31%), andmore often
had diabetes (31% vs. 25%), hypertension (82% vs. 77%), and prior MI (25%
vs. 16%). At 48 hours, MVD patients had higher rates of death/MI/IDR/ST
(6.3% v 4.2%, p¼<0.001), but not GUSTO severe bleeding (0.1% vs. 0.2%,
p¼0.71) compared with SVD patients. Consistent with outcomes in the
overall population, cangrelor resulted in fewer death/MI/IDR/ST events
comparedwith clopidogrel in patientswith SVD (3.9% v 4.5%; OR0.88, 95%
CI 0.67-1.15) and with MVD (5.4% vs. 7.3%; OR 0.73, 95% CI 0.59-0.91), p-
interaction¼0.31. 30-day Kaplan-Meier estimates of death/MI/IDR/ST are
shown in Figure 1. Bleeding rates were not different between cangrelor andclopidogrel in either SVD orMVD patients (SVD: OR 3.04; 95% CI 0.61-15.06;
MVD: OR 0.74; 95% CI 0.17-3.32; p-interaction 0.21).
CONCLUSIONS Patients with MVD compared to SVD had higher risk
of ischemic complications after PCI but not severe bleeding. Cangrelor
reduced ischemic complications compared with clopidogrel with
consistent reductions in higher risk MVD patients and lower risk SVD
patients with no signiﬁcant increase in severe bleeding.
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BACKGROUND Optimal duration of dual antiplatelet therapy (DAPT)
after percutaneous coronary intervention (PCI) for complex coronary
lesions and patients is still controversial. There is no randomized
study investigating shorter (6 months) vs. standard (12 months)
duration of DAPT after PCI for bifurcation lesions. We sought to report
the 18-month results of the bifurcation substudy from the I-LOVE-IT 2
trial, which compared safety and efﬁcacy between patients receiving
6- vs. 12-month DAPT after implantation of a novel biodegradable
polymer sirolimus-eluting stent (BP-SES).
METHODS In the prospective randomized I-LOVE-IT 2 trial, 1829 pa-
tients who were allocated to the BP-SES group were also randomized to
receive either 6-month (n¼909) or 12-month DAPT (n¼920) pre-stent-
ing; among them there were 717 patients (349 in 6-month DAPT group
and 368 in 12-month DAPT group, respectively) with bifurcation le-
sions. The major endpoints were target lesion failure (TLF, a composite
of cardiac death, target vessel myocardial infarction [TV-MI], or clini-
cally indicated target lesion revascularization [CI-TLR]) and net
adverse clinical and cerebral events (NACCE, a composite of all-cause
death, all MI, stroke, or major bleeding [Bleeding Academic Research
Consortium  type 3]) at 18 months. Landmark analyses at 6 months
were used to derive event rates between 6 and 18 months of follow-up.
RESULTS The demographic, lesion or procedural characteristics were
similar between groups. Eighteen-month TLF rate was numerically
higher in the 6-month DAPT group compared to the 12-month DAPT
group (9.3% vs. 5.5%, p¼0.055), which was mainly driven by an
increased CI-TLR between 6 and 18 months (3.5% vs. 1.1%, p¼0.03) in
the 6-month DAPT group when patients have discontinued DAPT.
There were no signiﬁcant differences in NACCE, death, MI, stroke, and
stent thrombosis (ST) at 18 months or between 6 and 18 months period
of follow-up. However, there was a non-signiﬁcant tendency of lower
all bleeding events in favoring 6-month DAPT strategy according to
the landmark analysis (1.2% vs. 3.3%, p¼0.056). Major clinical out-
comes were shown in table.
Table. Major Clinical Outcomes0-18 Months 6-18 Months (Landmark)6-month
DAPT Group
n [ 34912-month
DAPT Group
n [ 368 P6-month
DAPT Group
n [ 34712-month
DAPT Group
n [ 367 PTLF 9.3 (32) 5.5 (20) 0.055 4.0 (14) 1.6 (6) 0.052NACCE 8.7 (30) 6.6 (24) 0.30 2.6 (9) 3.0 (11) 0.74All-cause Death 2.0 (7) 1.7 (6) 0.71 1.4 (5) 1.4 (5) 1.00Cardiac Death 1.2 (4) 0.8 (3) 0.72 0.6 (2) 0.5 (2) 1.00All MI 5.8 (20) 4.1 (15) 0.31 1.2 (4) 0.5 (2) 0.44TV-MI 4.9 (17) 3.0 (11) 0.20 0.9 (3) 0.3 (1) 0.36Stroke 2.0 (7) 1.7 (6) 0.71 1.2 (4) 1.4 (5) 1.00Any
Revascularization6.1 (21) 5.5 (20) 0.74 4.9 (17) 3.3 (12) 0.27TVR 4.4 (15) 3.0 (11) 0.35 3.5 (12) 1.4 (5) 0.07CI-TLR 4.4 (15) 2.5 (9) 0.17 3.5 (12) 1.1 (4) 0.03All Bleeding 4.1 (14) 6.1 (22) 0.23 1.2 (4) 3.3 (12) 0.056Major Bleeding 0.3 (1) 0.6 (2) 1.00 0.3 (1) 0.3 (1) 1.00Deﬁnite/Probable
ST0.6 (2) 0.3 (1) 0.62 0 0 -CONCLUSIONS The present study indicates that 6 months of DAPT
might be insufﬁcient in patients after PCI (even with novel BP-SES) for
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future DAPT study focusing on personalized medicine is warranted.
(ClinicalTrials.gov Identiﬁer: NCT01681381)
CATEGORIES CORONARY: Pharmacology/Pharmacotherapy
KEYWORDS Bifurcation lesion, Biodegradable polymer, Dual anti-
platelet therapy
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BACKGROUND Patients with coronary artery disease who undergo
stent implantation and have concomitant indication for long term oral
anticoagulation represent a considerable percentage of the overall
population. To date there is still no consensus about the optimal
antithrombotic strategy to choose in this kind of patients, due to the
difﬁcult balance between an increased risk of bleeding and throm-
boembolic complications. Aim of this meta-analysis was to evaluate
risk and beneﬁts of triple antihrombotic therapy versus dual anti-
platelet therapy in patients undergoing coronary stent implantation,
requiring long term oral anticoagulation.
METHODS We performed formal searches of PubMed, EMBASE,
Cochrane central register of controlled trials and major international
scientiﬁc session abstracts from January 1990 to September 2014
regarding the use of triple antithrombotic therapy versus dual
antithrombotic therapy in patients undergoing percutaneous coronary
stent implantation that required chronic oral anticoagulation. Data
regarding study design, inclusion/exclusion criteria, number of pa-
tients, and selected endpoints was extracted by 2 investigators. Dis-
agreements were resolved by consensus.
RESULTS Twelve trials, with a total of 7838 patients undergoing stent
implantation with indication to long term oral anticoagulation were ﬁnally
included. A total of 2686 patients were treated with triple therapywhereas
5152 patients received dual antithrombotic therapy alone. The follow-up
period ranged from 270 to 2000 days. Mortality occurred in 10.8% of pa-
tients receiving triple therapy versus 16.7% of patients in dual therapy (OR
[95% CI] ¼ 0.80 [0.69-0.94], p ¼ 0.005; phet ¼ 0.0003). By meta-regres-
sion analysis no relationship was observed between reduction in mortality
and the risk of bleedings (p ¼ 0.10). Data regarding secondary endpoints
showed a signiﬁcant association between triple therapy and an increased
risk of bleedings (12.3% versus 9.9%) (OR [95% CI] ¼ 1.37 [1.16-1.62], p ¼
0.0002; phet ¼ 0.20), while we did not ﬁnd any signiﬁcant difference in
term of recurrence of myocardial infarction (p ¼ 0.39), stent thrombosis
(p ¼ 0.46) or stroke (p ¼ 0.15).
CONCLUSIONS This meta-analysis showed that among patients
undergoing coronary stent implantation, requiring chronic oral anti-
coagulation, the use of a triple antithrombotic therapy is associated with a
signiﬁcant reduction in mortality that largely outweighed the higher risk
of major bleeding complications associated with triple therapy.
CATEGORIES CORONARY: Pharmacology/Pharmacotherapy
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of CV death, MI, or stroke by 15-16% in PEGASUS-TIMI 54. We investigated
the efﬁcacy of ticagrelor in patients based on the presence and type of
stent.
METHODS Details of each patient’s most recent PCI were collected at
randomization. Stent thrombosis (ST) was prospectively adjudicated
according to ARC deﬁnitions with angiographic conﬁrmation when
available.
RESULTS In PEGASUS-TIMI 54, 4271 patients had no history of
stenting (20%), 8597 had a bare metal stent (BMS, 41%), and 8294 had
a drug-eluting stent (DES, 39%). The median time from PCI to
randomization was 1.7 yrs (IQR 1.2–2.3; 95% >1 year from PCI). Of the
patients with DES, 52% had received either everolimus or zotar-
olimus-eluting stents (EES or ZES), 27% had received sirolimus or
paclitaxel-eluting stents (SES or PES), and stent type was not speciﬁed
in the remainder. Among patients with stents randomized to placebo,
over a median of 33 months of follow-up, recurrent MI was most
frequent ischemic event (5.2%), followed by CV death (2.3%) and
stroke (1.7%), whereas ARC deﬁnite ST was rare (0.7%). Ticagrelor
consistently reduced CV death, MI, or stroke regardless of stenting or
stent type (pooled ticagrelor vs placebo; Fig Left) with similar
magnitude of beneﬁt for each dose and for each of the components.
Rates of deﬁnite ST were 0.38% with BMS, 1.01% with SES or PES,
and 0.65% with EES or ZES. Ticagrelor 90 mg bid signiﬁcantly
reduced ST whereas there was a trend with ticagrelor 60 mg bid
(Fig Right). The effect was even more pronounced for both doses
when patients were on study drug: HR 0.30 (0.14-0.65) & HR 0.66
(0.37-1.17), respectively.
CONCLUSIONS Patients with a history of MI more than 1 year from
PCI remain at heightened risk for ischemic events, predominantly MI,
CV death, and stroke, with stent thrombosis being rare. Long-term
ticagrelor reduces CVD/MI/Stroke regardless of stenting history and
reduces stent thrombosis in patients with stents.
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BACKGROUND In the CHAMPION PHOENIX trial, the potent, rapidly
acting, intravenous ADP antagonist cangrelor reduced the 48-hour
incidence of major adverse cardiac events (MACE; death, MI, stent
thrombosis, or repeat ischemia-driven revascularization) compared to
a loading dose of clopidogrel across a broad cross-section of patients
undergoing PCI. Whether this is true in patients with simple and
complex coronary anatomy is unknown.
